Cargando…
The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase–5 inhibitors
INTRODUCTION: Benign prostate hyperplasia and erectile dysfunction affect a significant subset of men. BPH and ED may have the same promoting conditions and are the strong predicting risk factors to each other. A significant number of these patients are bothered by lower urinary tract symptoms (LUTS...
Autor principal: | Wroński, Stanisław |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Polish Urological Association
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165684/ https://www.ncbi.nlm.nih.gov/pubmed/25247094 http://dx.doi.org/10.5173/ceju.2014.03.art20 |
Ejemplares similares
-
Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
por: Ferguson, James E., et al.
Publicado: (2013) -
Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy
por: Naito, Ryo, et al.
Publicado: (2021) -
Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 Inhibitors
por: Nunes, Isabelle Karine da Costa, et al.
Publicado: (2016) -
New Avenues for Phosphodiesterase Inhibitors in Asthma
por: Matera, Maria Gabriella, et al.
Publicado: (2021) -
A new therapeutic horizon in diaper dermatitis: Novel agents with novel action
por: Hebert, Adelaide A.
Publicado: (2021)